Skip to main content

Advertisement

SpringerLink
Log in

Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. Moreno C, Montserrat E . New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008; 22: 211–219.

    Article  CAS  PubMed  Google Scholar 

  2. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M . Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129–3140.

    Article  CAS  PubMed  Google Scholar 

  3. Huber S, Oelsner M, Decker T, zum Buschenfelde CM, Wagner M, Lutzny G et al. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 2011; 25: 838–847.

    Article  CAS  PubMed  Google Scholar 

  4. Messmer D, Fecteau JF, O’Hayre M, Bharati IS, Handel TM, Kipps TJ . Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 2011; 117: 882–889.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965–972.

    Article  CAS  PubMed  Google Scholar 

  6. Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, Burger M et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009; 69: 5424–5432.

    Article  CAS  PubMed  Google Scholar 

  7. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005; 115: 369–378.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Trentin L, Frasson M, Donella-Deana A, Frezzato F, Pagano MA, Tibaldi E et al. Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood 2008; 112: 4665–4674.

    Article  CAS  PubMed  Google Scholar 

  9. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G . Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003; 101: 1087–1093.

    Article  CAS  PubMed  Google Scholar 

  10. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F . The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009; 114: 3367–3375.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kim LC, Song L, Haura EB . Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6: 587–595.

    Article  PubMed  Google Scholar 

  12. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563–574.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Sandra Cabezas, Laura Jiménez and Jocabed Roldán for their technical support. This work was carried out, in part, at the Esther Koplowitz Center, Barcelona. Sorafenib was kindly provided by Bayer. This work was supported by grants from Ministerio de Ciencia e Innovación (SAF 09/9503), Redes Temáticas de Investigación Cooperativa de Cáncer from the Instituto de Salud Carlos III RED 2006-20-014 (DC), 2006-20-039 (EC) and RED2006-20-059 (EM), Fondo de Investigación Sanitaria (CP07/00072 and PI09/00060) (GR) and Generalitat Catalunya 2009SGR967 (DC). PP-G holds a contract from Ramón y Cajal program (Ministerio de Ciencia e Innovación, RYC2009-05134). SX-T and LR are recipients of predoctoral fellowships from Ministerio de Ciencia e Innovación (FPU) and IDIBAPS, respectively. ML-G and IS-V have a contract from RED 2006-20-014 and RED 2006-20-039, respectively.

Author information

Author notes

  1. M López-Guerra and S Xargay-Torrent: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Pathology, Hematopathology Unit, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

    M López-Guerra, S Xargay-Torrent, P Pérez-Galán, I Saborit-Villarroya, L Rosich, N Villamor, M Aymerich, G Roué, E Campo & D Colomer

  2. Department of Hematology, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

    E Montserrat

Authors
  1. M López-Guerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Xargay-Torrent
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Pérez-Galán
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Saborit-Villarroya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Rosich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Villamor
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Aymerich
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Roué
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Campo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E Montserrat
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D Colomer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Colomer.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

López-Guerra, M., Xargay-Torrent, S., Pérez-Galán, P. et al. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. Leukemia 26, 1429–1432 (2012). https://doi.org/10.1038/leu.2011.364

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.364

  • Springer Nature Limited

This article is cited by

Search

Navigation